Translating research into tangible benefits

Our team identifies opportunities that can lead to new drugs, vaccines and diagnostics, translating research into tangible benefits for the global community.

TRANSLATIONAL OUTCOMES

Translational research may lead to a better understanding of disease or identify new ways to treat, prevent or diagnose disease to enhance human health and wellbeing. This involves applying laboratory-based discoveries to clinical studies (bench to bedside) and can ultimately result in the production of a new treatment/diagnostic test which can be used in clinical and community settings. It can often take many years for a laboratory discovery to be tested and if found effective, applied into healthcare settings. From the laboratory bench to the patient’s bedside, translational outcomes are the ultimate goal of the Institute for Glycomics. With a track record of taking technologies to market and leadership focused on translational science, we have no doubt that we will be successful in discovering and developing the next generation of biomedical solutions.


Critical to delivering blockbuster technologies are two key factors:

  • Providing outstanding infrastructure
  • Assembling the brightest scientific minds through strategic appointments of research leaders of international standing, who demonstrate excellence in fundamental science while delivering commercial outcomes through translational science.

NEW MALARIA VACCINE TAKES CENTRE STAGE

A malaria vaccine to protect against all known strains of the deadly disease is being launched by the Institute for Glycomics.

Find out more

Clinical studies

Translational clinical studies, including clinical trials, allow the testing of laboratory-based findings in individuals who have volunteered to participate in that trial. There are different types of studies that may be undertaken depending on the aim of the research and these can include: collecting and analysing samples from individuals with a specific disease, examining the performance and effectiveness of new diagnostic tests and clinical trials which aim to assess the effectiveness of a new intervention eg an experimental drug or vaccine.

When a new intervention is being developed, early exploratory or pilot studies (sometimes referred to as phase 0 trials) may be conducted. This typically involves examining the intervention e.g. an experimental drug or a vaccine in a small number of volunteers over a limited time period.

Following this, clinical trials normally progress through four stages:

Phase I clinical trial

Tests a new intervention in a small number of volunteers (eg 20–80) to evaluate safety and tolerability (e.g. identify side effects and establish a safe dosage range, if required).

Phase II clinical trial

Evaluates the intervention in a larger group of volunteers (several hundred) to determine if it is effective and to gather additional safety information.

Phase III clinical trial

Examines the effectiveness of the intervention in larger groups of volunteers (several hundred to several thousand) by comparing it with no treatment or with other standard or experimental treatments. Side effects are also examined to gather additional safety information in a larger group of people.

Phase IV clinical trial

These are normally conducted after the intervention has been marketed. These studies monitor the effectiveness of the intervention in the general population and continue to collect information about side effects over a longer period of time. If the new intervention/diagnostic test performs well in Clinical Trials, it needs to be approved by the government before it is available for use in the general population. In Australia, new interventions and treatments are approved by the Therapeutic Goods Administration.

Want to know more?

Get in touch with the Institute for Glycomics